drug development process News
-
Pronalyse’s Fusion Protein Characterization Service Aids in the Drug Development Process
Pronalyse is a subdivision of Creative Proteomics, an integrated CRO company with rich experience in providing drug development services. Building on its years of experience, Creative Proteomics Pronalyse announces the launch of its fusion proteins characterization service to ensure the production of safe and effective therapeutic fusion proteins. Fusion protein refers to a new type of synthetic ...
-
Alfa Chemistry Leads the Way to Unleash Power of Computational Solutions in Solid State Chemistry for Pharmaceutical Research
In the ever-evolving field of pharmaceutical research, the hunt for effective drugs often rests on the ability to understand and manipulate the solid-state properties of compounds. Alfa Chemistry, a leading provider of research and development solutions, is taking the lead in harnessing the power of computational solutions in solid state chemistry to facilitate pharmaceutical research. ...
-
CD ComputaBio Announces 3D-QSAR Service for Drug Design and Screening
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company has recently launched 3D-QSAR services for scientists to accelerate the drug development process. Quantitative ...
-
Accelerating Drug Development with CD ComputaBio's Advanced Drug Design and CADD Solutions
CD ComputaBio, a reputable computational service provider in the field of biology, is dedicated to supporting research and trials by offering access to the latest software, technologies, and expertise at competitive prices and with fast turnaround times for researchers. Recently, the company introduced a series of state-of-the-art services in Drug Design and Computer-Aided Drug Design (CADD) with ...
-
Valo Health to Participate in UBS Biotechnology Virtual Private Company Symposium
Valo Health, Inc (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, announced that David Berry, founder & CEO of Valo will present at the UBS Biotechnology Virtual Private Company Symposium on September 22, 2022 from 11:30 AM EST to 11:55 AM EST. About Valo Health Valo Health, ...
-
Valo Health To Participate in Piper Sandler`s 34th Annual Healthcare Conference
Valo Health, Inc ("Valo"), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that its founder & CEO, David Berry, will present at Piper Sandler's 34th Annual Healthcare Conference at The Lotte New York Palace, New York, NY, on Thursday, December 1, 2022 at 8:10 AM (Kennedy 1, 4th ...
-
Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on ...
-
CD ComputaBio Unveils Ligand-based Pharmacophore Model Service for Drug Design and Screening
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company recently announced the launch of ligand-based pharmacophore model service for scientists to accelerate the ...
-
CD Formulation Enables Customized Synthesis Service for Osmotic Pressure Regulators for Drug Development
Normal cell function requires the maintenance of osmotic pressure. Therefore, in drug manufacturing, osmotic pressure regulators should be added to the formulation to avoid tissue damage. The US-based CRO company CD Formulation recently announced its ability to synthesize osmotic pressure regulators to suit the needs of different drug projects. These osmotic pressure regulators will help ...
-
CD Formulation Offers Forced Degradation Studies
To ensure the safety and efficacy of the drug product, chemical stability is of paramount importance. Earlier this month, CD Formulation announced its decision to launch forced degradation studies to help researchers find ways to promote drug stability. The forced degradation study, also known as stress testing, is carried out to produce representative samples for developing stability-indicating ...
-
Demand for Tessella’s Analytics Partnership confirms IDC analytics forecast
Tessella’s managed service for analytics, Tessella Analytics Partnership has welcomed five new blue chip customers in the last few months with consumer industries and life sciences enterprises particularly well represented. In May this year, IDC forecast that worldwide revenues for big data and business analytics will grow from nearly $122 billion in 2015 to $187 billion in 2019 in its ...
-
STALICLA strengthens pipeline to advance precision medicine for Autism Spectrum Disorders
STALICLA SA, a precision neuroscience clinical stage biotech advancing the first precision medicine platform for patients with Neurodevelopmental Disorders, has in-licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia. The first indication targets a biologically characterised subgroup of patients with Autism Spectrum Disorder (ASD) STALICLA's unique approach ...
By STALICLA
-
CD Formulation Offers Insights, Strategies, and Practical Suggestions on Pre-formulation Studies for Pharmaceuticals
In a recent statement, the US-based CRO company CD Formulation re-demonstrated its competence in drug development and announced that it now offers industry-leading insights, strategies, and practical suggestions on pre-formulation studies for drug developers worldwide. The past decade has witnessed a boom of new chemical entities development in the hope of bringing more therapies to diseases hard ...
-
Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes
Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. The protocols will be available for use on the BIO CELLX system ...
By CELLINK
-
Analyzing Delivery Systems: CD Formulation Introduces In Vitro Testing to Measure Microsphere and Microneedle Release
Researchers and scientists at CD Formulation, a leading pharmaceutical company, have achieved a breakthrough in drug delivery systems with the introduction of an innovative in vitro testing method. This method allows for the precise measurement of release rates for microspheres and microneedles, providing valuable insights for drug formulation and optimizing therapeutic outcomes. By incorporating ...
-
GI Innovation sings MoU for a new biopharmaceutical development with Merck
-Accelerating for development of high expression cell line through combination of GI-SMARTTM platform technology of GI Innovation and CHOZN® Platform of Merck -Expecting synergy of both companies for biopharmaceutical development using CHOZN® Platform, supplying subsidiary materials, education consulting, and etc.,. GI Innovation Co., Ltd. announced that it signed MoU for a ...
-
CD ComputaBio Boosts Small Molecule Drug Development with Protein-Small Molecule Docking Service
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise at competitive prices and with fast turnarounds for researchers. The company is pleased to announce the launch of the Protein-Small Molecule Docking service, designed to help customers quickly ...
-
Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions
Alfa Chemistry serves as an emerging pharmaceutical research organization with a mission to revolutionize the field of preclinical drug research with its wide range of comprehensive services. With a commitment to quality and excellence, Alfa Chemistry offers pharmacological analysis, drug safety evaluation, pharmacokinetic analysis, and bioanalytical services to streamline the drug development ...
-
STALICLA announces first patients enrolled in EU/US multicenter data collection biosampling study
The launch of the STA-B-001 study will accelerate the recruitment of participants for STP1 and STP2 Phase 2 trials. The multicenter trial will also enable deep clinical and biological data collection to strengthen STALICLA’s platform. Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine ...
By STALICLA
-
Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety
As a consulting and experimental service provider specializing in virology and microbiology, Creative Diagnostics recently introduced CC50/IC50 Assay service with a high level of assay sensitivity and accuracy. The CC50 and IC50 will be plotted using a sigmoidal dose-response curve, and the selectivity index (SI) for each compound is estimated by dividing the CC50 with the IC50. Pharmaceutical ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you